MedTrace Logo

Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD

NCT03216356 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2023-02-08

No results posted yet for this study

Summary

This study aims to investigate the utility of d-cycloserine (DCS) for enhancing the effect of a novel psychosocial intervention, imagery rescripting (ImRs), in adults with mild to moderate PTSD symptoms after experiencing a traumatic event such as sexual or physical assault, serious accident, etc. Participants will receive 4 sessions of either cognitive behavioral therapy with imagery rescripting or cognitive behavioral therapy with imaginal exposure and will receive study medication (DCS or Pill placebo) prior to Session 2 and Session 3.

Conditions

Interventions

BEHAVIORAL

CBT + ImRs

Cognitive Behavioral Therapy with Imagery Rescripting

BEHAVIORAL

CBT + I.E.

Cognitive Behavioral Therapy with Imagery Exposure

DRUG

D-Cycloserine

250 mg DCS (derived from Seromycin 250 mg capsules)

DRUG

Placebo

polyethylene glycol 3350 powder

DRUG

Study Pill

250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder

Sponsors & Collaborators

  • James S McDonnell Foundation

    collaborator OTHER

  • Boston University Charles River Campus

    lead OTHER

Principal Investigators

  • Joseph K Carpenter, M.A. · Boston University

  • Megan Pinaire, B.S. · Boston Universtiy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03216356 on ClinicalTrials.gov